News
Good news on rivaroxaban from Bayer

Just as effective as the standard therapy

Good news on rivaroxaban from Bayer

Bayer’s anticoagulant rivaroxaban is just as effective as the standard therapy for the treatment of deep vein thrombosis (DVT).  » more
Increasing oil content and combating disease in oilseed rape

Bayer CropScience’ goal is to make leading oilseed rape hybrids even more competitive

Increasing oil content and combating disease in oilseed rape
Bayer CropScience and the Oil Crops Research Institute (OCRI) in China have concluded two agreements.
» more
Collaboration on energy-efficient buildings

EcoCommercial Building

Collaboration on energy-efficient buildings
The EcoCommercial Building Program for sustainable construction continues to expand.
» more
Leading position in climate protection has been confirmed

Carbon Disclosure Leadership Index (CDLI)

Leading position in climate protection has been confirmed
Bayer has a leading position in climate protection and sustainable development.

» more
http://www.stockholders-newsletter-q3-2010.bayer.com/en/news.aspx

Copyright © Bayer AG

Print Page

Search

Download Center

Publications

Special Interest